Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
4TvpAPZ4yS3PQRy7